指南与共识乳腺US

英国和爱尔兰纤维腺瘤非活检实践:英国乳腺放射学会全国实践调查

Non-biopsy of fibroadenomas in the UK and Ireland: a British Society of Breast Radiology survey of national practice.
PubMed 文献 · Clin Radiol · 2025-06-24

该调查评估英国和爱尔兰55个乳腺单元对纤维腺瘤非活检的实践现状,发现55%使用「25岁以下」活检年龄范围,36%使用「30岁以下」,9%使用其他范围;所有使用「30岁以下」的单元均满意该阈值且审计确认安全;仅3个单元使用弹性成像辅助评估;结果支持将典型纤维腺瘤非活检扩展至30岁以下女性。

要点

  • 55个乳腺单元中,55%(30/55)的活检年龄上限为25岁以下,36%(20/55)为30岁以下,9%(5/55)为其他范围。
  • 使用「30岁以下」的20个单元均对该阈值满意,多数已审计且全部确认安全。
  • 30个仍使用「25岁以下」的单元中,29个愿意在获得明确指南或进一步证据后转为「30岁以下」。

核心结论

  • 调查结果反映实践正在发生变化,并支持皇家放射医师学院(Royal College of Radiologists)指南将典型纤维腺瘤的非活检扩展至30岁以下女性,前提是遵循严格的影像和临床标准。

研究设计与样本

  • 英国乳腺放射学会(BSBR)实践调查,分析来自英国和爱尔兰55个乳腺单元的数据,地理分布覆盖所有地区。

诊断标准与关键数值

  • 现行皇家放射医师学院(RCR)指南(由BSBR制定)推荐:25岁以下女性在满足严格影像标准时可安全避免针刺活检,经可靠审计可扩展至30岁以下。
  • 55%(30/55)的单元使用「25岁以下」活检年龄范围,36%(20/55)使用「30岁以下」,9%(5/55)使用其他年龄范围。

临床应用与阅片要点

  • 所有使用「30岁以下」的单元均对该阈值满意,多数已审计实践且全部确认安全。
  • 30个仍使用「25岁以下」的单元中,29个愿意在获得明确指南或进一步证据后转为「30岁以下」。
  • 仅3个单元在灰阶超声之外使用弹性成像评估纤维腺瘤,弹性成像可能支持决策但当前未广泛使用。
  • 各单元应通过可靠审计确保安全实践,并鼓励发表进一步证据以支持实施后的安全实践。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: Fibroadenomas are the commonest solid breast mass in young women. Current Royal College of Radiologists' (RCR) guidance, produced by the British Society of Breast Radiology (BSBR), recommends that needle biopsy can be safely avoided in women aged under 25, provided strict imaging criteria are met, but may be increased to under 30 years with robust audit. The aim was to assess national practice against current guidance prior to its planned update.

MATERIALS & METHODS: A BSBR survey of practice investigated non-biopsy of fibroadenomas in breast units across the UK and Ireland.

RESULTS: Data were analysed from 55 breast units, with a representative geographic spread across all nations. 30/55 units (55%) currently use the 'under 25 years' biopsy age range; 20/55 (36 %) use 'under 30 years', and 5/55 (9 %) use another age range. All units using 'under 30 years' are happy with the cut-off; most have audited their practice, all confirming it as safe. 29 of 30 units still using 'under 25 years' would be prepared to move to 'under 30' pending definitive guidance or further evidence. Only 3 units use elastography alongside greyscale ultrasound for assessing fibroadenomas.

CONCLUSION: Findings reflect an underlying change in practice and demonstrate support for RCR guidance to extend non-biopsy of typical fibroadenomas to women under 30 years, provided strict imaging and clinical criteria are followed. Although elastography may support decision-making, it is currently not in widespread use. Units should ensure safe practice through a robust audit. Further published evidence to support safe practice post-implementation is also encouraged.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Lowes S, Gibson E, Kulkarni T, et al. Non-biopsy of fibroadenomas in the UK and Ireland: a British Society of Breast Radiology survey of national practice. Clin Radiol. 2025. PMID: 40680628. doi:10.1016/j.crad.2025.106997

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。